"The Trump administration announced Tuesday that it has successfully negotiated lower prices for 15 drugs, including medications used for asthma, diabetes, arthritis and multiple forms of cancer. The list includes Ozempic and Wegovy, Novo Nordisk's drugs for Type 2 diabetes and weight management, as well as Rybelsus, Novo's oral GLP-1 for treating diabetes. The deal for cheaper prescription drugs grew out of an initiative put in place by the Inflation Reduction Act, the signature legislative package passed in 2022 during the Biden administration."
"The first wave of those negotiations happened last year, when the Biden administration secured pricing for 10 prescription drugs, including diabetes drug Januvia, arthritis drug Enbrel and Eliquis, which is used for blood clots. Many of the drugs the federal government wanted to make cheaper have life-saving applications. The new round of 15 drugs with lower prices came out of negotiation through that same process rather than Trump's "Most-Favored-Nation" plan to lower prescription drug prices through executive action and direct pressure on drug makers."
Medicare secured lower negotiated prices for 15 prescription drugs covering conditions such as asthma, diabetes, arthritis and various cancers. The list includes Ozempic, Wegovy and Rybelsus from Novo Nordisk. The price reductions resulted from the Inflation Reduction Act's authority allowing Medicare to negotiate directly with drug manufacturers. A previous round last year produced negotiated prices for 10 drugs, including Januvia, Enbrel and Eliquis. A separate deal earlier this month reduced prices for some weight-loss drugs in exchange for tariff relief. New pricing reflects what Medicare will pay drug companies, not consumer out-of-pocket costs.
Read at Fast Company
Unable to calculate read time
Collection
[
|
...
]